Tacrolimus Exposure and Mycophenolate Pharmacokinetics and Pharmacodynamics Early After Liver Transplantation

被引:2
|
作者
Saeves, Ingjerd [1 ,2 ]
Line, Pal-Dag [3 ]
Bremer, Sara [1 ]
Vethe, Nils T. [1 ]
Tveit, Ragnhild G. [1 ]
Meltevik, Tore J. [1 ]
Bergan, Stein [2 ,4 ]
机构
[1] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway
[2] Univ Oslo, Sch Pharm, Dept Pharmaceut Biosci, Oslo, Norway
[3] Oslo Univ Hosp, Dept Transplantat Med, Oslo, Norway
[4] Oslo Univ Hosp, Dept Pharmacol, Oslo, Norway
关键词
tacrolimus; mycophenolic acid; inosine monophosphate dehydrogenase; IMPDH; liver transplantation; therapeutic drug monitoring; RESISTANCE-ASSOCIATED PROTEIN-2; P-GLYCOPROTEIN; CLINICAL PHARMACOKINETICS; ACID GLUCURONIDE; MOFETIL; POLYMORPHISMS; DEHYDROGENASE; CYCLOSPORINE; EXPRESSION; RECIPIENTS;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Mycophenolic acid (MPA) and tacrolimus play important roles in immunosuppressive therapy after solid organ transplantation (Tx) and show large intra- and interindividual pharmacokinetic (PK) variabilities. The purpose of this study was to describe the intra-and interindividual variabilities of MPA and tacrolimus PKs during the first 3 weeks after adult liver transplantation. Furthermore, inosine monophosphate dehydrogenase activity was investigated. Materials: This study describes PK and pharmacodynamic parameters of MPA and the PKs of tacrolimus in 16 liver transplant recipients, in 4 follow-up periods (I-IV). Results: The area under the concentration-time curve (AUC(0-12 hours)) for tacrolimus was low early after Tx (eg, median 78.6 around day 4) and variable in all 4 periods ranging from 3.8 to 267 mu g h/L, whereas the predose concentrations (C-0) were 0.0-17.9 mu g/L. From periods I to IV, the tacrolimus dose was doubled and the median dose per body weight-adjusted AUC(0-12 hours) increased by 123% (P = 0.017). The AUC(0-12 hours) of MPA was in the range 8.6-57.4 mg h/L, with median values from 21.9 to 27.8 mg h/L, whereas C-0 was between 0.0 and 7.3 mg/L in the 4 periods (medians from 1.2 to 1.6 mg/L). The maximum inhibition of inosine monophosphate dehydrogenase within a dose interval ranged from 9.5% to 100%. Conclusions: This study confirmed the large variability in the PKs of tacrolimus and MPA in liver transplant recipients. In particular, the MPA AUC(0-12 hours) was consistently low in all 4 periods. We also observed a low tacrolimus exposure during the first days after transplant compared with the following weeks.
引用
收藏
页码:46 / 53
页数:8
相关论文
共 50 条
  • [1] Pharmacokinetics and Pharmacodynamics of Once-Daily Tacrolimus Compared With Twice-Daily Tacrolimus in the Early Stage After Living Donor Liver Transplantation
    Iwasaki, Mami
    Yano, Ikuko
    Fukatsu, Sachio
    Hashi, Sachiyo
    Yamamoto, Yuki
    Sugimoto, Mitsuhiro
    Fukudo, Masahide
    Masuda, Satohiro
    Nakagawa, Shunsaku
    Yonezawa, Atsushi
    Kaido, Toshimi
    Uemoto, Shinji
    Matsubara, Kazuo
    THERAPEUTIC DRUG MONITORING, 2018, 40 (06) : 675 - 681
  • [2] Population pharmacokinetics of mycophenolate mofetil in pediatric patients early after liver transplantation
    Wei, Yinyi
    Wu, Dongni
    Chen, Yiyu
    Dong, Chunqiang
    Qi, Jianying
    Wu, Yun
    Cai, Rongda
    Zhou, Siru
    Li, Chengxin
    Niu, Lulu
    Wu, Tingqing
    Xiao, Yang
    Liu, Taotao
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [3] Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation
    Yu, Meng
    Liu, Mouze
    Zhang, Wei
    Ming, Yingzi
    CURRENT DRUG METABOLISM, 2018, 19 (06) : 513 - 522
  • [4] Pharmacodynamics of tacrolimus in pediatric liver transplantation
    Staatz, CE
    Taylor, PJ
    Lynch, SV
    Tett, SE
    THERAPEUTIC DRUG MONITORING, 2003, 25 (04) : 536 - 536
  • [5] Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation
    Fontova, Pere
    Colom, Helena
    Rigo-Bonnin, Raul
    van Merendonk, Lisanne N.
    Vidal-Alabro, Anna
    Montero, Nuria
    Melilli, Edoardo
    Meneghini, Maria
    Manonelles, Anna
    Cruzado, Josep M.
    Torras, Juan
    Grinyo, Josep Maria
    Bestard, Oriol
    Lloberas, Nuria
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [6] Mycophenolate mofetil in combination with tacrolimus versus neoral after liver transplantation
    Klupp, J
    Glanemann, M
    Bechstein, WO
    Platz, KP
    Langrehr, JM
    Keck, H
    Settmacher, U
    Radtke, C
    Neuhaus, R
    Neuhaus, P
    TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) : 1113 - 1114
  • [7] Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation
    Staatz, CE
    Tett, SE
    CLINICAL PHARMACOKINETICS, 2004, 43 (10) : 623 - 653
  • [8] Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation
    Christine E. Staatz
    Susan E. Tett
    Clinical Pharmacokinetics, 2004, 43 : 623 - 653
  • [9] Population pharmacokinetics of tacrolimus early after liver transplantation: why therapeutic drug monitoring is mandatory
    Petitcollin, A.
    Tron, C.
    Rayar, M.
    Houssel-Debry, P.
    Camus, C.
    Lalanne, S.
    Lemaitre, F.
    Boudjema, K.
    Bellissant, E.
    Verdier, M. C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 13 - 13
  • [10] Successful early steroid withdrawal using a tacrolimus and mycophenolate protocol for liver transplantation
    Hassanein, T
    Freeman, J
    Oculam, CA
    Albanese, L
    Zamora, JU
    Wahlstrom, HE
    Linda, L
    HEPATOLOGY, 1996, 24 (04) : 1579 - 1579